Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
Phase 2
Completed
NCT05068752
| Condition | Pancreas Cancer |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | HonorHealth Research Institute |
|---|
| Status | Completed |
|---|
| Enrollment | 10 participants |
|---|
| Interventions | Vemurafenib, Sorafenib |
|---|
| Start date | Oct 28, 2021 |
|---|
| Completion date | Nov 8, 2024 |
|---|
| Results posted | Mar 30, 2026 |
|---|
Summary
The purpose of this research is to determine the benefit of two oral chemotherapy drugs, Vemurafenib and Sorafenib, in individuals with KRAS mutated pancreatic cancer who have progressed on standard chemotherapy.
Disease Control Rate (DCR)
Initiation of study treatment until 16 weeks. · DCR, % of participants with CR/PR/SD
| Vemurafenib in Combination With Sorafenib | 0 DCR, % of participants with CR/PR/SD |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.